GBI Magazine spoke to Dr Caroline Barelle, Founder of Elasmogen, to talk about her Start-Up journey, and how the Deepbridge Life Sciences EIS scheme influenced it.
This is the second part of our four part series with Deepbridge, looking at the Start-Ups empowered by the Deepbridge Life Sciences EIS. Founded in 2010, Chester-based Deepbridge launched its first EIS fund in the 2013/14 tax year and specialises in providing venture capital to early-stage technology, life sciences and renewable energy companies.
Caroline is an example of the type of founders Deepbridge invest in, someone who is flexible and ambitious. Moreover Elasmogen the company is also an exemplar of the sort of Start-Up Deepbridge invest in with the Deepbridge Life Sciences EIS. Elasmogen pioneers biologics for inflammatory, autoimmune diseases and oncology.
In this interview Caroline helps detail the science behind her company, explaining how Elasmogen has the potential to help millions of people through its soloMER technology.
If you would like to invest in Elasmogen, or find out more about the companies invested in by the Deepbrige Life Sciences EIS, please see their website here.
